Osimertinib Combinations as Second-Line Treatment in Non-Small Cell Lung Cancer: The Jury’s Still Out
Note Should a VEGF inhibitor (bevacizumab/Avastin) be combined with osimertinib or not?
The role of osimertinib combinations as second-line treatment for advanced non-small cell lung cancer (NSCLC) is still unclear, according to researchers.
Osimertinib is a standard first-line treatment option for patients with advanced NSCLC and EGFR mutations, but progression on this treatment is inevitable, said Ross Soo, MD, of the National University Cancer Institute in Singapore.
He noted that preclinical data have implicated the angiogenic pathway in resistance to EGFR tyrosine kinase inhibitors (TKIs). Therefore, studies in the second-line setting are evaluating whether the efficacy of single-agent osimertinib can be improved with the addition of a VEGF inhibitor or other agents. Read more.